Bolt Biotherapeutics, Inc. (BOLT): Price and Financial Metrics
GET POWR RATINGS... FREE!
BOLT Stock Price Chart Interactive Chart >
BOLT Price/Volume Stats
|Current price||$1.80||52-week high||$19.29|
|Prev. close||$1.75||52-week low||$1.39|
|Day high||$1.83||Avg. volume||243,279|
|50-day MA||$2.14||Dividend yield||N/A|
|200-day MA||$7.04||Market Cap||67.45M|
Bolt Biotherapeutics, Inc. (BOLT) Company Bio
Bolt Biotherapeutics, Inc. operates as a biotechnology company. The Company develops immune-stimulating antibody conjugates, a new class of cancer therapeutics, which systemically-administered and uncover the immune system to induce anti-tumor immunity. Bolt Biotherapeutics serves healthcare industry in the United States.
Most Popular Stories View All
BOLT Latest News Stream
|Loading, please wait...|
BOLT Latest Social Stream
View Full BOLT Social Stream
Latest BOLT News From Around the Web
Below are the latest news stories about Bolt Biotherapeutics Inc that investors may wish to consider to help them evaluate BOLT as an investment opportunity.
Las Vegas, USA, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight Toll-Like Receptor Agonist Pipeline constitutes 45+ key companies continuously working towards developing 45+ Toll-Like Receptor Agonist treatment therapies, analyzes DelveInsight DelveInsight''s Toll-Like Receptor Agonist Pipeline Insight 2022'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Toll-Like Receptor Agonist pipeline domain. Some of the essential takeaways from the Toll-Like Receptor Agonist Pipeline report: DelveInsight''s Toll-Like Receptor (TLR) Agonist...
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
REDWOOD CITY, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that management will present at two upcoming conferences in February: Guggenheim 2022 Oncology Virtual ConferenceFireside chat on Wednesday, Feb. 9, at 10:00 a.m. PT (1:00 p.m. ET)Virtual 1
Penny stocks are incredibly risky and should only be considered with speculation funds.
Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors
REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ: BOLT ), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that the first patient has been dosed in a new combination arm of the ongoing multi-center, multi-dose Phase 1/2 clinical trial of BDC-1001. This arm is evaluating BDC-1001 in combination with Bristol Myers Squibb''s PD-1 checkpoint inhibitor OPDIVO® (nivolumab). In parallel, Bolt continues to advance the single-agent portion of the study, following the presentation of interim dose-escalation data at the European Society of Medical Oncology Immuno-Oncology (ESMO I-O) Congres...
BOLT Price Returns